# Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

> **NCT05023655** · PHASE2 · TERMINATED · sponsor: **Prisma Health-Upstate** · enrollment: 20 (actual)

## Conditions studied

- Solid Tumor
- ARID1A Gene Mutation

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT05023655
- **Lead sponsor:** Prisma Health-Upstate
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-06
- **Primary completion:** 2026-03-06
- **Final completion:** 2026-03-06
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Ipsen has discontinued all active tazemetostat clinical trials and expanded access programs due to the emergence of a clinically unfavorable benefit risk profile for tazemetostat in combination with lenalidomide and rituximab.
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023655, "Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05023655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*